Hvsen Biotechnology Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Hvsen Biotechnology Co., Ltd. carries a market capitalization of 4.77B, placing it among publicly traded companies globally. Its enterprise value stands at 3.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.77B |
| Enterprise Value | 3.31B |
Share Statistics
Hvsen Biotechnology Co., Ltd. currently has 202.33M shares outstanding.
| Shares Outstanding | 202.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hvsen Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 23.27. The price-to-sales ratio is 2.18, and the price-to-book ratio stands at 6.02.
| PE Ratio | 23.27 |
| PS Ratio | 2.18 |
| PB Ratio | 6.02 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | 28.85 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hvsen Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 19.55 and an EV/FCF ratio of 20.92. The EV/Sales ratio of 2.09 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.55 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.09 |
| EV / EBITDA | 19.55 |
| EV / EBIT | 19.55 |
| EV / FCF | 20.92 |
Financial Position
Hvsen Biotechnology Co., Ltd. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.97, indicating elevated leverage, while an interest coverage ratio of 5.16 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.57 |
| Quick Ratio | 0.64 |
| Debt / Equity | 16.97 |
| Debt / EBITDA | 2.07 |
| Interest Coverage | 5.16 |
Financial Efficiency
Hvsen Biotechnology Co., Ltd. posts a return on equity of 30.19 and a return on invested capital of 6.19.
| Return on Equity (ROE) | 30.19 |
| Return on Assets (ROA) | 5.04 |
| Return on Invested Capital (ROIC) | 6.19 |
| Return on Capital Employed (ROCE) | 15.05 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.67 |
Taxes
Over the trailing twelve months, Hvsen Biotechnology Co., Ltd. has paid 19.64M in income taxes, reflecting an effective tax rate of 11.60.
| Income Tax | 19.64M |
| Effective Tax Rate | 11.60 |
Stock Price Statistics
Hvsen Biotechnology Co., Ltd.'s stock has gained approximately 12.6371% over the past 52 weeks. The 50-day moving average sits at 23.47, while the 200-day moving average is 23.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | 12.6371% |
| 50-Day Moving Average | 23.47 |
| 200-Day Moving Average | 23.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hvsen Biotechnology Co., Ltd. generated 1.59B in revenue and converted that into 148.90M in net income, yielding earnings per share of 0.84. EBITDA reached 169.20M, while operating income came in at 169.20M.
| Revenue | 1.59B |
| Gross Profit | 339.61M |
| Operating Income | 169.20M |
| Pretax Income | 169.29M |
| Net Income | 148.90M |
| EBITDA | 169.20M |
| EBIT | 169.20M |
| Earnings Per Share (EPS) | 0.84 |
Balance Sheet
Hvsen Biotechnology Co., Ltd. holds 514.18M in cash and equivalents against 350.45M in total debt, resulting in a net debt position of 94.16M. Total book value stands at 575.30M, with working capital of 459.33M providing operational flexibility.
| Cash & Cash Equivalents | 514.18M |
| Total Debt | 350.45M |
| Net Debt | 94.16M |
| Equity (Book Value) | 575.30M |
| Book Value Per Share | 3.47 |
| Working Capital | 459.33M |
Cash Flow
After subtracting -129.16M in capital expenditures, free cash flow totaled -129.16M - equivalent to -0.78 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -129.16M |
| Free Cash Flow | -129.16M |
| FCF Per Share | -0.78 |
Margins
Hvsen Biotechnology Co., Ltd. operates with a gross margin of 21.41, reflecting its pricing power and cost economics. The operating margin of 10.67 and net profit margin of 9.39 provide insight into operational efficiency.
| Gross Margin | 21.41 |
| Operating Margin | 10.67 |
| Pretax Margin | 10.67 |
| Profit Margin | 9.39 |
| EBITDA Margin | 10.67 |
Dividends & Yields
The company's payout ratio of 24.98 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.23 |
| Dividend Yield | N/A |
| Payout Ratio | 24.98 |
| Shareholder Yield | 4.63 |
| FCF Yield | 3.47 |
Stock Splits
Hvsen Biotechnology Co., Ltd.'s most recent stock split took place on May 10, 2021 with a 2:3 split ratio.
| Last Split Date | 5/10/2021 |
| Split Ratio | 2:3 |
Scores
Hvsen Biotechnology Co., Ltd. posts an Altman Z-Score of 3.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.43 |